Stock Analiz

60 Degrees Pharmaceuticals, Inc. SXTP

Biotechnology: Pharmaceutical Preparations · IPO 2023 · data as of November 13, 2026

$0.52Market cap $2M
Open the interactive analysis →

60 Degrees Pharmaceuticals, Inc. (SXTP) is a healthcare company listed in the US with a market value of about $2M. In the twelve months to June 30, 2026 it had revenue of $1M and net income of -$8M, a net margin of -729.9%.

Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -176%.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2023. Revenue went from $223208 in 2022 to $1M in 2025, growth of about 65.2% a year. It was profitable in 0 of the last 4 years in our data. Its share count rose by 6661% over three years (dilution for shareholders). It spends 209% of revenue on research and development.

Score: 1.2 / 5

Value0/5
Future growth4/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year revenue growth above 8% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S1.6
P/B0.7
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-488.3%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)65.5%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-1573.8%
ROIC (5-yr avg.)-175.8%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 4 years

Fiscal yearTTM2025202420232022
Revenue$1M$1M$607574$253573$223208
Net income-$8M-$7M-$8M-$4M-$6M
Free cash flow-$9M-$7M-$6M-$5M-$1M
EPS (diluted)$-9.92$-11.73$-74.17$-236.68$-623.37
Net margin-729.9%-732.5%-1308.0%-1485.1%-2769.5%
ROIC—-214.6%-231.8%-80.9%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does 60 Degrees Pharmaceuticals pay a dividend?

Not currently.

Is 60 Degrees Pharmaceuticals a good stock to buy?

We do not give buy or sell advice. 60 Degrees Pharmaceuticals scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.